DMRA Stock — Damora Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a biopharmaceutical company developing therapies for the treatment of hematologic disorders. In our previously announced Asset Acquisition (as defined below), we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms (“MPNs”), a group of related, chronic disorders of the bone marrow.

Source: 10-K FY2025 via SEC EDGAR

Share price

$23.70

Market cap

$1,467.1M

Cash

$528.5M

Enterprise value

$938.6M

Balance sheet

Cash	$528.5M
Debt	$0.0M
Net cash	$528.5M
Enterprise value	$938.6M
Basic shares	61.9M shares
Fully diluted shares	86.6M shares
Fully diluted market cap	$2,051.3M
Cash per share	$8.54
Quarterly burn	$21.9M
Cash runway	24.7 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

61.7M

Pre-funded warrants

0.0M

Options

4.5M

RSUs

1.0M

Warrants

0.6M

Converts

0.0M

Conv preferred

18.1M

ESPP reserve

0.6M

FDSO

86.6M

Cap table as of 2026-06-30.

Price history

Loading DMRA daily closes…

Loading price history…

Next catalyst

DMR-002 · Est. Nov 7, 2026 · half midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now half midpoint	DMR-002 first regulatory submission	Not disclosed	first regulatory	2H 2026
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	DMR-003 first regulatory submission	Not disclosed	first regulatory	2027
GUIDEDEst. Jul 16, 2027 in 7 mo guidance midpoint	DMR-001 Phase 1/1b CLARITY-101 in mutCALR-driven ET and MF	Phase 1/1b	mutCALR-driven ET and MF	beginning mid-2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

DMR-001

Phase 1 · Active Modality: monoclonal antibody (subcutaneous)

Target mutCALR

Partnerships Paragon Therapeutics: option exercised Dec 8, 2025; exclusive license under negotiation; $1.25M research initiation fee; up to $22M milestones per product ($2.5M on first Phase 1 dosing); low-to-mid single-digit royalties; annual Paramora warrants (1% fully diluted)

Indications

Essential thrombocythemia (ET) (Phase 1)
Myelofibrosis (MF) (Phase 1)

Catalysts

— beginning mid-2027
— mid-2028

Status note Lead candidate; anti-mutCALR monoclonal antibody. Phase 1/1b trial in ET/MF recently initiated (health authority approval in first country); expansion cohorts planned next year.

DMR-002

Preclinical · Active

Target mutCALR

Partnerships Paragon Therapeutics: option exercised Apr 28, 2026; same economic terms as DMR-001

Indications

MPN (mutCALR-driven) (Preclinical)

Catalysts

— second half of 2026

Status note Second anti-mutCALR candidate. First regulatory submission planned 2H 2026.

DMR-003

Preclinical · Active Modality: bispecific T cell engager

Target mutCALR / CD3

Partnerships Paragon Therapeutics: option available, not yet exercised; same economic terms

Indications

MPN (mutCALR-driven) (Preclinical)

Catalysts

— 2027

Status note Bispecific CD3 x anti-mutCALR T cell engager. Paragon option not yet exercised; IND/CTA planned 2027.

GB3226

Stage not disclosed · Active Modality: small molecule

Target ENL-YEATS / FLT3

Indications

Acute myeloid leukemia (AML) (Stage not disclosed)

Status note Legacy asset. Deprioritized in Mar 2026 portfolio review as company focuses on mutCALR portfolio; company intends to explore partnerships or collaborations to advance it. Not explicitly discontinued.

GB1211

Stage not disclosed · Active

Target galectin-3

Indications

not disclosed (Stage not disclosed)

Status note Legacy galectin-3 inhibitor candidate; deprioritized Mar 2026; company intends to explore partnerships. Limited disclosure in excerpts.

GB2064

Stage not disclosed · Active

Target LOXL-2

Indications

not disclosed (Stage not disclosed)

Status note Legacy LOXL-2 inhibitor candidate; deprioritized Mar 2026; company intends to explore partnerships. Limited disclosure in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	DMR-001
Lead indication	Myeloproliferative Neoplasms (MPNs)
Lead phase	Phase 1
Active trials	0

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Avoro Capital Advisors	3,783,000	no change	0.88%	2026-08-14
RA Capital Management	2,399,702	+392	0.54%	2026-08-14
Braidwell LP	1,620,377	+725,531	1.56%	2026-08-14
Perceptive Advisors	1,223,000	no change	0.49%	2026-08-14
Cormorant Asset Management	1,000,000	-525,000	1.33%	2026-08-14
Ikarian Capital	335,710	no change	1.43%	2026-08-14
ADAR1 Capital Management	280,000	+1,000	0.34%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

DMRA — Damora Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Specialist fund holders

Latest news

DMRA — Damora Therapeutics Inc.